
Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer
Treatment with apalutamide (Erleada) demonstrated consistent 24-month overall survival (OS) data between real-world patients with metastatic castration-sensitive prostate cancer (mCSPC) and those treated in the phase 3 TITAN trial (NCT02489318).1 These …